Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesenCell for steroid-refractory chronic graft-versus-host disease after allogeneic transplant
RBR-22jd7g5Phase 1Not yet recruiting
- Sponsor
- Pontifícia Universidade Católica do Paraná
- Start
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in chronic graft-versus-host disease (cGVHD), sponsored by Pontifícia Universidade Católica do Paraná. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on RBR-22jd7g5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-22jd7g5.